Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Sponsor: Novartis Pharmaceuticals
Summary
The main purpose of this multicenter, randomized, double-blind, placebo-controlled Phase 2b study is to investigate the safety and efficacy of GIA632 in participants with NSV and to identify the optimal dose to be promoted into the confirmatory Phase 3 program.
Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase IIb Study to Assess the Efficacy and Safety of GIA632 in Adult Participants With Non-segmental Vitiligo Followed by an Extension Period
Key Details
Gender
All
Age Range
18 Years - 99 Years
Study Type
INTERVENTIONAL
Enrollment
210
Start Date
2026-03-09
Completion Date
2030-02-14
Last Updated
2026-04-06
Healthy Volunteers
No
Conditions
Interventions
GIA632
GIA632 will be administered during the 48-week core period.
Placebo
Placebo will be administered during the 48-week core period.
Locations (10)
Cahaba Derm and skin hlth ctr 27
Birmingham, Alabama, United States
Clinical Trials Research Institute
Thousand Oaks, California, United States
Miami Derm and Laser Institute
Miami, Florida, United States
Dawes Fretzin Clinical Rea Group
Indianapolis, Indiana, United States
Revival Research Institute
Troy, Michigan, United States
Austin Inst for Clinical Research
Pflugerville, Texas, United States
Novartis Investigative Site
Sydney, New South Wales, Australia
Novartis Investigative Site
Waitara, New South Wales, Australia
Novartis Investigative Site
Mississauga, Ontario, Canada
Novartis Investigative Site
Toronto, Ontario, Canada